CMPX

Compass Therapeutics, Inc. (CMPX) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. The company operates in a single segment focused on research and development (R&D) of drug candidates targeting angiogenesis and the immune system. As of March 31, 2026, the company had 180.1 million shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by $1.7 million (10%) compared to Q1 2025, driven primarily by higher operating expenses.
• Expense Growth: Total operating expenses rose by $2.3 million. G&A expenses increased by $2.0 million (41%), largely due to a $2.0 million increase in stock-based compensation. R&D expenses increased slightly by $0.3 million (3%).
• Interest Income: Interest income increased by $0.6 million to $2.0 million, reflecting higher yields on marketable securities.
• Liquidity Position: Total cash and marketable securities decreased from $208.9 million at year-end 2025 to $194.7 million at March 31, 2026, despite a net cash inflow from investing activities of $38.4 million (net sales of securities).
• Share Count: Weighted average shares outstanding increased to 186.4 million from 138.2 million in the prior year, including 6.7 million pre-funded warrants.

Outlook, Management Commentary, and Risks

• Clinical Progress (Tovecimig): In April 2026, the company announced updated data for its lead candidate, tovecimig, in biliary tract cancer (BTC). The combination with paclitaxel showed a statistically significant improvement in Progression-Free Survival (4.7 months vs. 2.6 months) and Overall Survival compared to control. Tovecimig received Orphan Drug Designation from the FDA in April 2026.
• Regulatory Strategy: Management intends to meet with the FDA to discuss the BTC data in advance of a planned Biologics License Application (BLA) submission.
• Liquidity Outlook: Management expects current cash resources ($195 million) to fund operating expenses and capital expenditures into 2028. No revenue is expected in the near future.
• Risks: The company faces standard biotech risks, including the uncertainty of clinical trial outcomes, regulatory approval, and the need for substantial additional funding. Failure to raise capital could force delays in development or commercialization.
• Stock-Based Compensation: Unrecognized stock-based compensation cost as of March 31, 2026, totaled $50.0 million, to be recognized over future periods.

Key Investor Verification Points

• Cash Runway: Verify the sustainability of the "into 2028" funding estimate given the burn rate of ~$17.3 million per quarter in operating cash flow.
• BLA Submission Timeline: Confirm the specific timeline for the planned FDA meeting and subsequent BLA submission for tovecimig following the April 2026 data release.
• Dilution Risk: Monitor the impact of the 24.9 million potentially dilutive shares (options and RSUs) currently excluded from diluted EPS calculations due to anti-dilutive effects.
• Manufacturing Accruals: Note the $5.9 million in accrued manufacturing expenses for tovecimig, indicating significant near-term cash outflows for production.
• Collaboration Milestones: Review potential future milestone payments under the ABL Bio and Adimab agreements, which could impact future cash flows.